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A large prostate tumor expressing keratin 8 
(red) in a male transgenic mouse 
overexpressing ERG in prostate epithelial 
cells. A small fragment of normal prostate 
gland expressing keratin 5 in basal cells 
(green) and keratin 8 in luminal cells (red) is 
present at the bottom right corner of the 
image. Cell nuclei are in blue. 
 






ERG is a transcription factor of the ETS (erythroblastosis virus E26) family that is rearranged and 
overproduced in approximately 50% of all human prostate tumors. ERG overproduction appears to 
be important because knockdown of ERG in a human prostate cancer cell line (VCaP) that 
overexpresses ERG has been shown to decrease cell invasion, a hallmark of metastasis. 
Conversely, overexpression of ERG in non-cancerous prostate epithelial cells (RWPE-1) results in a 
marked increase in cell invasion. However, whether overexpression of ERG is sufficient for prostate 
cancer development and the potential molecular mechanisms of ERG in prostate cancer have not 
been determined. A new Fred Hutch study from Dr. Valeri Vasioukhin’s Laboratory (Human Biology 
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Division), in collaboration with Dr. Pete Nelson’s Laboratory (Human Biology, Clinical Research, and 
Public Health Sciences Divisions), tackled this question by providing a detailed characterization of a 
mouse model wherein ERG is overexpressed in the prostate epithelium at levels comparable to 
those observed in ERG-rearranged human prostate cancers. This study was recently published in 
Cancer Cell. 
The authors first generated a mouse model that expressed clinically relevant levels of ERG 
specifically in the prostate epithelium. They found that these mice were short-lived, and that half of 
them developed late-onset prostate tumors. This finding demonstrated that overproduction of ERG in 
prostate epithelial cells in vivo is sufficient for prostate cancer development, indicating that 
rearrangement and overproduction of ERG plays a causal role in prostate cancer initiation. The 
researchers then analyzed expression of gene targets of major signaling pathways known to 
regulate cancer development, and found that even before tumor development, the ERG-
overexpressing prostate epithelial cells exhibited high activity of YAP1 (Yes-associated protein 1). 
Because YAP1 is a transcriptional regulator and a key effector of the Hippo signaling tumor 
suppressor pathway, the investigators used RNA sequencing to compare the transcriptional profiles 
of RWPE-1 cells overexpressing either ERG, a constitutively active form of YAP1 (YAP1S127A), or 
both ERG and YAP1S127A. Gene set enrichment analysis of the RNA sequencing data revealed 
strong overlap between the ERG and YAP1 transcriptional programs.  
Next, the researchers investigated the functional relevance of YAP1, and its close relative TAZ, 
using a 3D prostate organoid culture system. These experiments revealed that knockdown of either 
YAP1 or TAZ blunted both the proliferation and the invasive properties of human RWPE-1 cells that 
overexpressed ERG. To address the mechanism by which ERG promotes high YAP1 activity, the 
authors performed chromatin immunoprecipitaiton followed by high throughput DNA sequencing 
(ChIP-seq) to identify DNA sequences bound by ERG and TEAD4, a YAP1 binding partner. ChIP-
seq experiments in both VCaP and RWPE-1 cells revealed that ERG and TEAD4 were co-bound at 
many Hippo pathway genes, and that ERG increased both histone acetylation and gene activation at 
these sites. Importantly, 44% (52 of 116) of primary human prostate cancers analyzed co-expressed 
ERG and YAP1, and expression of nuclear YAP1 was linked to tumor recurrence after treatment.  
To evaluate the role of YAP1 in ERG-driven tumors in vivo, the investigators administered an FDA-
approved inhibitor of YAP1 (Verteporfin) to pre-established human orthotopic xenografts tumors, and 
found that Verteporfin treatment suppressed the growth of ERG-positive, but not ERG-negative, 
prostate tumor xenografts. Finally, the authors addressed whether activation of YAP1 was sufficient 
for tumor formation by driving expression of YAP1S127A in the prostate epithelium, which resulted in 
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late-onset prostate tumors that were strikingly similar to ERG-driven tumors, both in histology and 
transcriptional profile. 
Said Dr. Vasioukhin, "ERG is overexpressed in ~50% of human prostate cancers, but the role and 
mechanisms of ERG in prostate cancer remained poorly understood. This study demonstrated that 
ERG expression is sufficient to cause prostate cancer development in aged individuals and revealed 
a connection between ERG and the Hippo signal transduction pathway, which can explain the 
molecular mechanisms of ERG in prostate cancer initiation." In conclusion, this important study 
showed that overexpression of either ERG or YAP1 results in late-onset prostate tumors and it 
revealed the mechanism responsible for oncogenic function of ERG. Furthermore, since YAP1 
activity is required for ERG-driven tumors both in vitro and in vivo, it suggests that the YAP1 
antagonist Verteporfin may provide novel therapeutic opportunities. 
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